(Q24246471)

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Acute and long-term safety and tolerability of risperidone in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Risperidone in a very young child with PDD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Self injurious behavior in autism: clinical aspects and treatment with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Risperidone for aggression and self-injurious behavior in adults with mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Risperidone and explosive aggressive autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Use of risperidone in a paediatric population: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Effects of risperidone on aberrant behavior in persons with developmental disabilities: II. Social validity measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Short-term efficacy and safety of risperidone in young children with autistic disorder (AD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. Research Units on Pediatric Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Risperidone and adaptive behavior in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Autism spectrum disorders: early detection, intervention, education, and psychopharmacological management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Antipsychotics in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

The epidemiology of autism: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

The Yale-Brown Obsessive Compulsive Scale. II. Validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Behavior checklist for identifying severely handicapped individuals with high levels of autistic behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Autism diagnostic observation schedule: a standardized observation of communicative and social behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Pharmacotherapeutic management of autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Auditory integration training and other sound therapies for autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

The developmental, dimensional and diagnostic interview (3di): a novel computerized assessment for autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

The Nisonger Child Behavior Rating Form: age and gender effects and norms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

Intravenous secretin for autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

A scale for rating symptoms of patients with the syndrome of autism in real life settings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005040.PUB2